immunowatch...companies all over the world are partnering up during this global health crisis in...
TRANSCRIPT
Special edition - 1st UPDATE 29/05/20
IMMUNOWATCH
COVID-19
2
I N T R O D U C T I O NMabDesign and the COVID-19 pandemic
The French immunotherapy network is facing unprecedented challenges and uncertainties as a result of the COVID-19 pandemic. Now more than ever, there is a need for rapid development of both preventive and curative treatments and facilitated access to information, resources and potential collaborators. Since the beginning of the disease outbreak, MabDesign has been continuously adapting its actions and services to respond to those needs. Our latest and ongoing contribution to the fight against COVID-19 is through this special edition of Immunowatch and its regular updates.
MabDesign’s Immunowatch is a one-of-a-kind information monitoring newsletter in the field of immunotherapy which aims at providing members of our association with the most recent and relevant data gathered or generated through the key expertise of MabDesign and its collaborators in scientific research, business intelligence, market analysis and intellectual property. Its original format has been modified to cater for the fast evolution of the response to the COVID-19 pandemic and allow rapid and pertinent updates. Immunowatch is done in collaboration with the MAbMapping Unit of the Ambition Recherche & Développement (ARD) Biomédicaments 2020 Phase II programme, funded by the Centre Val de Loire region.
3
4. Editorial
5. COVID-19: Treatment, Vaccines and Diagnostics
9. The French response to COVId-19
12.
15. Scientific literature on covid-19
7. Global Collaboration for the fight against COVID-19
Upcoming Mabdesign events ON COVID-19
Funding and aid for the covid-19 response
COVID-19 and intellectual property19.
21.
Table of content
Mankind’s history has been marked by various outbreaks of infectious diseases
across centuries with several of them reaching global proportions. Amidst
this COVID-19 pandemic, the scientific committee at large must once again
rise up to the challenge of providing fast solutions to this new health crisis.
Since the beginning of the outbreak, various actors from the immunotherapy
field have been continuously joining the fight in keeping at bay the severe
acute respiratory syndrome coronavirus 2 SARS-CoV-2, causative agent of
the current pandemic. All over the world, vaccines and therapies are being
researched and developed in the hope of keeping millions safe or saving them.
France’s immunotherapy network obviously responded to this call of arms against
COVID-19. Several pharmaceutical and biotechnology companies are even setting the pace
in key aspects of this pandemic response through innovative or repurposed products and
services. Others have joined forces with both local and foreign partners to enhance their
R&D capabilities. Together, they are working relentlessly towards combatting SARS-CoV-2.
In these uncertain times, MabDesign is fully committed to supporting its members
and the immunotherapy network in general. All our services have been maintained
since the beginning of the lockdown. In parallel, we have adapted our training
offers and have modified our forthcoming scientific events. We are monitoring
closely the current situation so as to make any necessary amendments to our
services and actions. Finally, MabDesign has been actively contributing to the
COVID-19 pandemic response which includes this special edition of Immunowatch.
Editorial
Immunowatch - Special edition covid-19 | 1ST UPDATE
COVID-19: Message from MabDesign president,Francis Carré
4
COVID-19: Treatment, vaccines and diagnostics*
Sites of clinical trials (#)
Stage of development (#)
96% 4%
Interventional Observational
Type of clinical studies
Significant increase in the pipeline in a matter of weeksKey figures
533
658
1807
48%
Companies developing atleast one product
Unique molecules in the pipeline
Clinical trials
Ongoing trials
* All data has been generated by MabDesign unless stated otherwise
+101%
Drugs206
Drugs414
Drugs528
Drugs658
Clinical trials422
Clinical trials1013
Clinical trials1334
Clinical trials1807
+140%
+31%
+27%
+35%
+25%
01/04 21/04 30/04 25/05
368
295
387
196
86 8165 58 50 45 37
55
China UnitedStates
Europe Iran Spain France India Italy UnitedKingdom
Canada Germany Others
76
185
89
119
4
97
11
63
36
Prop
hylac
tic V
accin
e
Ther
apeu
tic
Prop
hylac
tic V
accin
e
Ther
apeu
tic
Prop
hylac
tic V
accin
e
Ther
apeu
tic
Prop
hylac
tic V
accin
e
Ther
apeu
tic
Ther
apeu
tic
Discovery Preclinical Phase I Phase II Phase III
5
COVID-19: Treatment, vaccines and diagnostics*
Immunotherapy as frontline treatment for COVID-19
Several types of immunotherapy are being evaluated in the hope of providing solutions to tackle the COVID19 pandemic.
Several COVID-19 diagnostics tools are already available
+168
Commercially available tests
34% 13% 13% 19%
The antibody pipeline
Vaccine technology used
Sub-unit mRNA DNA Recombinant vector
Majors companies developing: mRNA vaccines- ModeRNA, CureVAc , Translate Bio, BioNtech, ETheRNA DNA vaccines- Innovio Pharmaceuticals, Linea Rx, AnGes
Tackling the COVID-19 pandemic does not only involve therapeutic or preventive treatments but also rapid and effective diagnostics tools.
5% 2% 14%
Inactivated Live attenuated Others
Type of testType of test11
% o
f p
ipel
ine
* All data has been generated by MabDesign unless stated otherwise1. Latest update 26/05/2020 Source : https://www.360dx.com/coronavirus-test-tracker-launched-covid-19-tests
PCR: polymerase chain reaction, direct detection of the virus through amplification of its genetic materialSerological: Detection of virus-specific antibodies which are produced by the immune system
Type of immunotherapy being developed
Polyclonal Antibody14%
Bispecific Monoclonal Antibody
1%
Monoclonal Antibody
83%
Monoclonal Antibody
Conjugated2%
29 28
17
64
16
6
gLOBAL COLLABORATION FOR THE FIGHT AGAINST covid-19
Companies all over the world are partnering up during this global health crisis in order to develop a treatment. Such collaborative endeavours go beyond the realms of the healthcare sector and include IT companies offering innovative solutions.
+155
Partnering agreements between healthcare companies
Selection of latest major deals related to COVID-19Announced date
deal description Type of product
26/05/20 Merck aquires Themis Biosciences and partners with IAVI and Ridgeback Biotherapeutics
Vaccine and antiviral products
08/05/20 Sorrento Therapeutics and Mount Sinai Health System to Enter into Partnership to Develop Antibody for COVID-19
Antibody
30/04/20 AstraZeneca Enters into Co-Development Agreement with University of Oxford for COVID-19 vaccine
Vaccine
27/04/20 Merck and Institute for Systems Biology Enter into Research Collaboration for COVID-19
Unknown
23/04/20 ReiThera Enters into Agreement with LEUKOCARE and Univercells for COVID-19 Vaccine
Vaccine
22/04/20 Precision For Medicine Enters into Partnership with Karyopharm Therapeutics for COVID-19
Small molecule
21/04/20 Bayer to Enter into Research Partnership with Population Health Research Institute (PHRI) to Identify COVID-19 Treatments
Small molecule
16/04/20
Dynavax Technologies and Sinovac Biotech Enter into Collaboration to Develop COVID-19 Vaccine
Vaccine
08/04/20 CSL Behring and SAB Biotherapeutics Enter into Partnership for COVID-19 Antibody
05/04/20 GlaxoSmithKline and Vir Biotech to Enter into Collaboration for COVID-19 Antibody
03/04/20 GlaxoSmithKline Enters into Agreement with Xiamen Innovax Biotech for COVID-19 Vaccine
Vaccine
02/04/20 Emergent BioSolutions Enters into Agreement with US Government to Develop Plasma-Derived Therapy for COVID-19 Patients
Antibody
02/04/20 Amgen and Adaptive Biotechnologies to Enter into Licensing Agreement to Develop Antibodies to Treat COVID-19
Antibody
26/03/20 Twist Bioscience Enters into Agreement with Vanderbilt University Medical Center to Supply Critical Products and Identify Antibody Therapeutics for COVID-19
Antibody
26/03/20 Ology Bioservices Enters into Agreement with Inovio Pharma to Manufacture COVID-19 DNA Vaccine
Vaccine
Source: GlobalData
7
gLOBAL COLLABORATION FOR THE FIGHT AGAINST covid-19
Selection of latest major deals involving French companies
Announced date
deal description Type of product
13/05/20 Eurobio Scientific SA, an in vitro medical diagnostics company, has partnered with Hospices Civils de Lyon (HCL), to develop a bank of anti-SARS CoV-2 antibodies
Antibody
11/05/20 ABL applies its expertise in custom manufacturing virus-based therapeutics to accelerate the Institut Pasteur and Themis’ coalition COVID-19 vaccine development
Vaccine
24/04/20 To fight the Covid-19 pandemic, Owkin launches the Covid-19 Open AI Consortium (COIA), to bring innovative discoveries and concrete results to medical research.
Others
22/04/20 Valneva and Dynavax Technologies Enter into Collaboration to Advance Vaccine Development for COVID-19
Vaccine
15/04/20 LFB and the biotech company Xenothera sign an agreement for the production of the first clinical batch of a drug candidate
Antibody
14/04/20
Sanofi and GlaxoSmithKline to Enter into Co-Development Agreement for Covid-19 Vaccine
06/04/20 CSL Behring Enters into Co Development Agreement with Takeda Pharma, Biotest, Bio Products Laboratory, LFB and Octapharma for Treatment of COVID-19
Antibody
27/03/20 Sanofi Pasteur Enters into Co-Development Agreement with Translate Bio to Develop Novel mRNA Vaccine Candidate Against COVID-19
Vaccine
Source: GlobalData
8 Immunowatch - Special edition covid-19 | 1ST UPDATE
The french responseto COVID-19
The French immunotherapy network
Companies involved directly in the COVID19 response
Companies providing solutions and collaborations
Since the beginning of the outbreak in France, MabDesign has been making an inventory of its members from the French immunotherapy network involved directly in the fight against COVID-19 to showcase their expertise and/or help them identify new collaborators. Below is the latest update of this inventory. The latter and the corresponding database (see below) is updated weekly.
MabDesign has also created an online database summarizing the involvement and expertise of every entity listed above. The database can be accessed here together with the contact list here.
9
BiatechFrance
Theranovir
The french responseto COVID-19
In France, there has been a rapid mobilization of key actors of the pharmaceutical and healthcare sectors to join this combat against COVID-19 by initiating, pursuing or enhancing their activities to provide innovative solutions and develop efficient treatments. MabDesign has been monitoring and communicating regularly on this pertinent information to our network. We here summarized these latest activities pertaining to the development of therapeutic products and/or diagnostics tools.
BioSpeedia (spin-off from Institut Pasteur) has developed a one step rapid test for Novel Coronavirus SARS-CoV-2 IgM/IgG in serum, plasma, fingertip blood or whole blood samplesof pneumonitis patients or suspected cases.
Eurobio Scientific has announced the CE marking for its EBX 041 SARS CoV2 proprietary test, developed specifically for the clinical diagnosis of COVID-19. This is a multiplex kit with three targets: two for identifying the virus and one target for a control integrated into each patient test.
Eurofins has developed several testing and service offering to support healthcare practitioners and authorities around the world as well as the biopharmaceutical industry respond to the COVID-19 crisis.
Companies developing diagnostics tests
CLEAN CELLS is currently developing its own COVID-19 detection tests pour biological products (raw material or end products) in line with regulatory bodies.
.IDvet has launched a new serological test to detect antibodies against COVID‐19 with a specificity of 99.9%, significantly lowering the rate of false positive results. More than a million tests have already been produced.
AAZ has developed COVID-PRESTO®, a rapid serological test to identify immunization (apparently protective) against COVID-19.
Poly-Dtech has launched several serological tests to identify individuals immunised or not against COVID-19.
10 Immunowatch - Special edition covid-19 | 1ST UPDATE
The french responseagainst COVID-19
OSE Immunotherapeutics has announced a new COVID-19 prophylactic vaccine program.
Eukarÿs is making the C3P3 system available to any academic research team working on the biology of the SARS-CoV-2 virus in support of the scientific community mobilized against the 2019 coronavirus pandemic.
Abivax receives ANSM and Ethics Committee clearance to test its development candidate ABX464 in 1,034 Covid-19 patients in randomized Phase 2b/3 clinical trial.
Pasteur Institute is currently working on three different COVID19 vaccine R&D projects.
RevImmune COVID-19 program is proposing the use of IL-7 (CYT107) to prevent patients who are in the hospital for COVID-19 from progressing to having to be treated in the ICU or progressing to needing more than 4L/minute of supplemental oxygen.
AB Science has been granted authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19.
OSIVAX is currently working on a large spectrum vaccine against coronaviruses.
Plate-Forme CHEM-Symbiose has joined the multidisciplinary, large-scale virtual screening project to look at 1.5 billion small molecules in order to identify candidate compounds that are likely to inhibit the SARS-CoV-2 virus.
Pharnext and the University Hospital Institute Méditerranée Infection announce a joint effort to evaluate repurposed drugs for potential use against the covid-19 virus.
Apteeus has decided to share its unique collection of molecules TEE Library®, with several research teams from the Institut Pasteur de Lille are currently working on Covid19 to explore the opportunities for drug repositioning to fight corona viruses.
Signia Therapeutics is using its SIGNATURA® platform to repurpose drugs in view of finding new therapeutic solutions against COVID-19.
Companies developing treatment or vaccines
ARE YOU INVOLVED IN THE COVID-19 RESPONSE?Register to our inventory or send us your latest news
Our team will be communicating regularly on all the French companies and institutions involved directly or indirectly in the pandemic response. To join the inventory, please fill in the online questionnaire here or send your latest news to our communication department ([email protected])
11
Funding and Aid for the COVID-19 response
Funding schemes
International
National Institutes of Health (NIH) R34 Clinical Trial Planning Grants- Deadline: 07/09/2020
https://www.niams.nih.gov/grants-funding/conducting-clinical-research/grants/planning-grants
European
Coronavirus research and innovation Deadline: 01/09/2020
https://ec.europa.eu/info/research-and-innovation/research-area/health-research-and-innovation/coronavirus-research-and-innovation_en
AI and robotics solutions for the COVID-19 crisis. Deadline: 31/12/2020
https://ec.europa.eu/eusurvey/runner/15e8809f-a702-fff6-b68d-9b69f98cdc2b
Fast-track co-creation funding for COVID-19 related activities. Deadline: 30/06/2020
https://www.eosc-portal.eu/fast-track-co-creation-funding-covid-19-related-activities
AMable Call for Solution Ideas to COVID-19 challenges. Deadline: 01/10/2020
https://www.amable.eu/calls/call-for-proposals
PRACE support to mitigate impact of COVID-19 pandemic. Deadline: not specified
https://prace-ri.eu/
European Commission New COVID-19 related calls. Deadline: 11/06/2020
https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-search
Space Based Services-Applications Addressing COVID-19 Outbreak. Deadline: 15/11/2020
https://business.esa.int/funding/invitation-to-tender/space-based-services-applications-addressing-covid-19-outbreak
12 Immunowatch - Special edition covid-19 | 1ST UPDATE
Funding and Aid for the COVID-19 response
Funding schemesFrench
Programme d’investissements d’avenir (PIA) : appel à projets pour développer des solutions thérapeutiques préventives ou curatives contre le Covid-19. Deadline :30/09/2020
https://www.gouvernement.fr/programme-d-investissements-d-avenir-un-appel-a-projets-pour-developper-des-solutions-therapeutiques
RAPID (régime d’appui à l’innovation duale). Deadline : none
https://www.defense.gouv.fr/aid/deposer-vos-projets/subventions/rapid
Appel à Projets Structurants Pour la Compétitivité spécifique à la crise sanitaire COVID-19. Deadline :30/09/2020
https://www.bpifrance.fr/A-la-une/Appels-a-projets-concours/PSPC-COVID-19-49161
Appel à projets thématique Covid-19 - Accélérateur 21 La Croix Rouge
https://21-croix-rouge.fr/programme-entrepreneuriat/
L’intelligence artificielle pour une expérience améliorée du système de santé. Deadline : 01/07/2020
https://www.health-data-hub.fr/appel-a-projets
Appel à projets Recherche-Action sur COVID-19 (coronavirus disease 2019) RA-COVID-19. Deadline : 28/10/2020
https://anr.fr/fr/detail/call/appel-a-projets-ra-covid-19/
L’appel à projet TOUS UNIS CONTRE LE VIRUS de Foundation France. Deadline : not specified
https://www.fondationdefrance.org/fr/tous-unis-contre-le-virus-la-fondation-de-france-lap-hp-et-linstitut-pasteur-lancent-un-appel-la
13
Funding and Aid for the COVID-19 response
Funding schemesRegional (More information on the websites of the various French health clusters)
DIM ELICIT projets mettant en œuvre des technologies ou des méthodes innovantes en lien avec l’analyse, le diagnostic et/ou le traitement pour combattre le SARS-CoV2 en Ile de France. Deadline : 31 décembre 2020.
https://www.defense.gouv.fr/aid/deposer-vos-projets/subventions/rapid
STOP COVID 2nde édition - Appel à projets régional flash Etat-Bpifrance/Région Centre-Val de Loire. Deadline: 22/07/2020
https://www.devup-centrevaldeloire.fr/actualites/stop-covid-2nde-appel-projets-regional-etat-bpifrance-centre-loire-237.html
Appel à projets santé exceptionnel 2020 en Alpes-Maritimes. Dealine : 20/07/2020
https://www.departement06.fr/appels-a-projets/soutien-aux-equipes-medicales-et-scientifiques-du-departement-pour-des-innovations-techniques-dans-le-domaine-de-la-sante-35665.html
COVID-19 Therapeutics Accelerator by Bill & Melinda Gates Foundation, Wellcome, and Mastercard
https://www.gatesfoundation.org/TheOptimist/coronavirus
Coalition Innovation Santé face à la crise sanitaire du Covid-19
Other notable endevours
https://www.coalitioncovid.org/
Coalition for Epidemic Preparedness Innovation (CEPI)
https://cepi.net/
BioM-COVID-19 exchange platform
https://app.jogl.io/program/opencovid19
National mapping of the different initiatives linked to the French response to COVID-19
The six French Health Clusters namely, Atlanpole Biotherapies, BioValley France, Eurobiomed, Lyonbiopôle,Medicen and Clubster NSL have joined forces to create this national mapping. Read the press release here and access the mapping here.
14 Immunowatch - Special edition covid-19 | 1ST UPDATE
Scientific literature on covid-19
As of going to press, more than 70001 scientific articles on the current COVID19 pandemic have been published in 2020 worldwide. The aim of this section is obviously not to cite all of them but rather to provide an overview of the translational nature of the research work being conducted on the virus and the outbreak.
A Novel Coronavirus from Patients with Pneumonia in China, 2019.Zhu N, Zhang D et al. N Engl J Med. 2020 doi: 10.1056/NEJMoa2001017.
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.Dai W, Zhang B et al. Science. 2020 doi: 10.1126/science.abb4489.
COVID-19 and artificial intelligence: protecting health-care workers and curbing the spread.Mcall B. Lancet Digit Health. 2020 doi: 10.1016/S2589-7500(20)30054-6.
SARS-CoV-2: a storm is raging.Pedersen SF, Ho YC. J Clin Invest. 2020 doi: 10.1172/JCI137647.
Early dynamics of transmission and control of COVID-19: a mathematical modelling study.Kucharski AJ, Russell TW et al. Lancet Infect Dis. 2020 doi: 10.1016/S1473-3099(20)30144-4.
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry Wan Y, Shang J et al. J Virol . 2020 doi: 10.1128/JVI.02015-19.
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.Hoffmann M, Kleine-Weber H et al. Cell. 2020 doi: 10.1016/j.cell.2020.02.052.
1. Keword search on Pubmed.gov on 26/04/20 for ‘COVID19’’ OR ‘Sars Cov 2’ OR ‘219-nCOV’ OR ‘‘novel coronavirus’ with 2020 as year of publication 15
Scientific literature on covid19
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.Ascierto PA, Fox B et al. J Immunother Cancer. 2020 doi: 10.1136/jitc-2020-000878.
Estimates of the severity of coronavirus disease 2019: a model-based analysis.Verity R, Okell LC et al. Lancet Infect Dis. 2020 Mar 30. doi: 10.1016/S1473-3099(20)30243-7.
Clinical and immunological features of severe and moderate coronavirus disease 2019.Chen G, Wu D et al. J Clin Invest. 2020 doi: 10.1172/JCI137244.
A highly conserved cryptic epitope in the receptor-binding domains of SARS CoV-2 and SARS-CoV.Yuan M, Wu NC et al. Science. 2020 doi: 10.1126/science.abb7269.
Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding.Lu R , Zhao X et al. Lancet 2020 doi: 10.1016/S0140-6736(20)30251-8.
The COVID-19 pandemic and research shutdown: staying safe and productive.Omary MB, Eswaraka J et al. J Clin Invest. 2020 doi: 10.1172/JCI138646.
Cytokine release syndrome in severe COVID-19.Moore BJB, June CH. Science. 2020 Apr 17. doi: 10.1126/science.abb8925.
Structure of Mpro from COVID-19 virus and discovery of its inhibitors.Jin Z, Du X. Nature. 2020 doi: 10.1038/s41586-020-2223-y.
16 Immunowatch - Special edition covid-19 | 1ST UPDATE
Scientific literature on covid19
Pathological Inflammation in Patients With COVID-19: A Key Role for Monocytes and Macrophages.Merad M, Martin J C. Nat Rev Immunol. 2020 doi: 10.1038/s41577-020-0331-4.
Neutralizing Antibodies Against SARS-CoV-2 and Other Human Coronaviruses.Jiang S, Hillyer C et al. Trends Immunol; 2020 doi: 10.1016/j.it.2020.03.007
A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping.Romano M, Ruggiero A et al. Cells. 2020 doi: 10.3390/cells9051267.
Immunogenicity of a DNA Vaccine Candidate for COVID-19.Smith T R F, Patel A et al. Nat Commun. 2020 doi: 10.1038/s41467-020-16505-0.
Viral and Host Factors Related to the Clinical Outcome of COVID-19.Zhang X, Tan Y et al. Nature 2020, doi: 10.1038/s41586-020-2355-0.
The Sinai Immunology Review Project, Immunology of COVID-19: current state of the science.Vabret N, Britton G J et al. Immunity 2020, doi: 10.1016/j.immuni.2020.05.002
Chemistry and Biology of SARS-CoV-2.Domling P, Chao C et al. Chem 2020, doi : 10.1016/j.chempr.2020.04.023
Proteomics of SARS-CoV-2-infected Host Cells Reveals Therapy Targets.Bojkova D, Klann K et al. Nature. 2020, doi: 10.1038/s41586-020-2332-7.
17
Scientific literature on covid19
Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19.Park H, Iwasaki Y. Cell Host & Microbe (2020), doi: 10.1016/j.chom.2020.05.00.
Spiking Pandemic Potential: Structural and Immunological aspects of SARS-CoV-2.Wang Y T, Landeras-Bueno S et al. Trends in Microbiology 2020, doi :10.1016/j.tim.2020.05.012
Respiratory virus infections: Understanding COVID-19.Subbarao K , Mahanty S et al. Immunity 2020, doi: 10.1016/j.immuni.2020.05.004.
The Many Faces of the anti-COVID Immune Response. Vardhana S A, Wolchok J D et al. J Exp Med. 2020, doi: 10.1084/jem.20200678.
Replication of SARS-CoV-2 in Human Respiratory Epithelium.Milewska A, Kula-Pacurar A et al. J Virol 2020, doi: 10.1128/JVI.00957-20.
Preventing Cytokine Storm Syndrome in COVID-19 Using α-1 Adrenergic Receptor Antagonists.Konig M F, Powell M et al. J Clin Invest. 2020, doi: 10.1172/JCI139642.
Herd Immunity: Understanding COVID-19.Randolph H E, Barreiro L B et al. Immunity. 2020, doi: 10.1016/j.immuni.2020.04.012.
18 Immunowatch - Special edition covid-19 | 1ST UPDATE
COVID-19 and intellectual property
Both innovative and routine approaches are being used in this global involvement of developing effective diagnostics tools and treatment for COVID-19. These rely partly or solely on proprietary technologies, expertise, scientific know-how and molecules whether serving their intended use or having being repurposed. In parallel, we are already observing the appearance of a COVID19-specific patent landscape within months only of the outbreak at its epicenter in Wuhan. We here provide a summary of these patent applications.
Title Technology domains
Patent Number
Application date
Primer for amplifying nucleotide fragment of novel coronavirus (SARS-CoV-2) gene and application thereof
Biotechnology CN111154923 2020-04-07
Method for high-throughput detection of respiratory viruses by using second-generation sequencing and application
Biotechnology CN111139315 2020-04-03
Small interfering nucleic acid for inhibiting novel coronavirus, composition and application
Pharmaceuticals CN111139241 2020-04-03
Microfluidic immunofluorescence kit for novel coronavirus excrement detection
Analysis of biological materials
CN210534159U 2020-03-31
Medical image detection method, device, equipment and storage medium
Computer technology
CN111127466 2020-03-31
COVID-19 nucleic acid detection kit for novel coronavirus and use method thereof
Biotechnology CN111118228 2020-03-31
Medicinal composition for strengthening body resistance and rescuing lung and application
Pharmaceuticals CN111110824 2020-03-26
Hospital building epidemic prevention system based on 5G Internet of things
Digital Communication
CN111121976 2020-03-26
Coating liquid of novel coronavirus recombinant antigen, pretreatment method, application and product
Analysis of biological materials
CN111122879 2020-03-26
A novel and reliable rt pcr based detection method for corona virus (2019) infection
Biotechnology IN202011013176 2020-03-25
Novel coronavirus whole genome capture method, primer group and kit
Biotechnology CN111118226 2020-03-25
Novel coronavirus IgG antibody enzyme-linked immunoassay kit and detection method thereof
Pharmaceuticals CN111122864 2020-02-06
19
COVID-19 and intellectual property
Title Technology domains
Patent Number
Application date
Colloidal gold kit for joint detection of novel coronavirus IgM/IgG antibody and preparation method thereof
Analysis of biological materials
CN111089962 2020-03-25
Inactivated virus sample RNA preservation solution and preparation method thereof
Biotechnology CN111088319 2020-03-25
Method and device for screening new coronary pneumonia candidate drugs
Pharmaceuticals CN111081316
2020-03-25
Kawach: an iot based covid-19 precaution and hygiene alert device
Digital Communication
IN202011012796 2020-03-24
Compositions, kits, methods and uses for detecting and typing viruses causing respiratory tract infections
Biotechnology CN111074011
2020-03-23
Detection kit for new coronavirus, influenza A and influenza B and respiratory syncytial virus
Biotechnology CN111088408 2020-03-20
Novel coronavirus detection kit based on visual lamp and detection method thereof
Biotechnology CN111154921 2020-03-19
Fluorescence immunochromatography device for detecting COVID-19 and using method thereof
Analysis of biological materials
CN111060691 2020-03-17
Application of LTX-315 in preparation of products for inhibiting coronavirus
Pharmaceuticals CN111150833 2020-03-16
Multiplex fluorescent quantitative PCR detection kit and detection method for SARS-COV-2 virus
Biotechnology CN111139317 2020-03-13
Primer-probe combination for detecting 6 respiratory viruses, kit and application
Biotechnology CN111041129 2020-03-13
Rapid detection 2019-nCoV replication kit and application
Biotechnology CN111074009 2020-03-10
Novel nucleic acid kit for rapidly detecting 2019-nCoV and application thereof
Biotechnology CN111074010 2020-03-10
Novel coronavirus ORF1ab gene nucleic acid detection kit Biotechnology CN111020064 2020-03-10
Source: Orbit patent database. Keyword search for ‘novel coronavirus’ Or ‘COVID19’ or ‘SARS-CoV-2’ under independent claims, title or abstract. Patents were then analysed individually for pertinence. Patents with no abstract or description were excluded.
20 Immunowatch - Special edition covid-19 | 1ST UPDATE
Mabdesign upcomingevents ON COVID-19
The 4th Edition of the Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2020) will be held in Lyon, France on December 9-10, 2020 and will largely address the current COVID-19 pandemic as well as other infectious diseases. The I4ID2020 will include keynote lectures, pitch talks of new innovative projects, industrial talks from pharmaceutical companies and poster presentations. Moreover, there will be several opportunities for networking, companies to showcase their new products and technologies as well as dedicated time for business partnering, through an online B2B platform. So go to the website or contact us ([email protected]) to subscribe or to know more about the event and the sponsoring offers.
https://www.i4id.org/
21
Mabdesign’s reponseduring the covid19 pandemic
MORE NEWS ARE ON THE WAY!To be kept in the loop, register to our newsletter
Our different departments will be providing regular updates of the COVID-19 pipeline, the inventory of companies involved in the response, the latest French news and the patent landscape
through our newsletter. Register here.
MABDESIGN is a French membership organization in the field of immunotherapy. Created in 2014 MABDESIGN is managed by four competitivity clusters (Atlanpole Biotherapies, Eurobiomed, Lyonbiopole, Medicen) and three pharmaceutical companies (LFB, Pierre Fabre and Sanofi), and one biotech (DBV Technologies).
Operational since September 2015, MABDESIGN has over 170 members, including pharmaceutical and biotechnology companies, service providers, training organizations, and equipment suppliers at the cutting edge of technology.
About MabDesign
•
•
Bât. L’Initial17 , rue Crépet
69007 LyonTél. 04 78 02 39 88
Follow us on
@Mabdesign_fr
MabDesign